Physician profile
Phoebe Shinn
NPI 1952464133
$1,220.01
in general payments reported to CMS, 2019-2025
10 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $575 · 2024: $345 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $289.44 | 2024-2025 | Omnipod, Omnipod |
| Tandem Diabetes Care, INC. | $130.44 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $128.47 | 2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $124.68 | 2023 | Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $122.75 | 2024 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $110.20 | 2023 | Andexxa |
| Idorsia Pharmaceuticals US INC | $108.21 | 2023 | Quviviq |
| Novo Nordisk INC | $103.60 | 2023 | Wegovy |
| Corcept Therapeutics | $88.33 | 2025 | Korlym |
| Mannkind Corporation | $13.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phoebe Shinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.